(Q46022302)

English

Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.

scientific article published on 7 May 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

phase II clinical trial

0 references

B-cell lymphoma

1 reference

based on heuristic

inferred from title

marginal zone B-cell lymphoma

1 reference

based on heuristic

inferred from title

11

object named as

Cheolwon Suh

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

author name string

Sung Yong Oh

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Won Seog Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Dae Ho Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Seok Jin Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Sung Hyun Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Baek Yeol Ryoo

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Hye Jin Kang

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Young Jin Choi

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Joo Seop Chung

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Hyo Jung Kim

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

publication date

7 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

28

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

171-177

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS10637-009-9260-6

21 January 2018

Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High relapse rate in patients with MALT lymphoma warrants lifelong follow-up.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nongastric marginal zone B-cell lymphoma: analysis of 247 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine in the management of metastatic breast cancer: a systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of deoxycytidine kinase in gemcitabine cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current role of gemcitabine in the treatment of Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on MALT lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19421710

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-009-9260-6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19421710

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46022302&oldid=2207537188"